Bruker Corporation (BRKR)
NASDAQ: BRKR · Real-Time Price · USD
36.77
+0.09 (0.25%)
Mar 9, 2026, 2:54 PM EDT - Market open
Bruker Revenue
In the year 2025, Bruker had annual revenue of $3.44B with 2.08% growth. Bruker had revenue of $977.20M in the quarter ending December 31, 2025, a decrease of -0.25%.
Revenue (ttm)
$3.44B
Revenue Growth
+2.08%
P/S Ratio
1.62
Revenue / Employee
$301,553
Employees
11,396
Market Cap
5.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.44B | 70.10M | 2.08% |
| Dec 31, 2024 | 3.37B | 401.90M | 13.56% |
| Dec 31, 2023 | 2.96B | 433.80M | 17.14% |
| Dec 31, 2022 | 2.53B | 112.80M | 4.67% |
| Dec 31, 2021 | 2.42B | 430.40M | 21.66% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Globus Medical | 2.94B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Integer Holdings | 1.85B |
| Masimo | 1.53B |
| Penumbra | 1.40B |
| LivaNova | 1.39B |
| Haemonetics | 1.32B |
BRKR News
- 12 days ago - Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR - Business Wire
- 13 days ago - Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications - Business Wire
- 14 days ago - Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum - Business Wire
- 14 days ago - Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology - Business Wire
- 24 days ago - These Analysts Cut Their Forecasts On Bruker Following Q4 Results - Benzinga
- 25 days ago - Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Bruker Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Business Wire